DEXCOM INC (DXCM) Stock Fundamental Analysis
NASDAQ:DXCM - Nasdaq - US2521311074 - Common Stock - Currency: USD
Overall DXCM gets a fundamental rating of 6 out of 10. We evaluated DXCM against 187 industry peers in the Health Care Equipment & Supplies industry. DXCM scores excellent on profitability, but there are some minor concerns on its financial health. DXCM is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings could make DXCM a good candidate for growth investing.
1. Profitability
1.1 Basic Checks
In the past year DXCM was profitable.
In the past year DXCM had a positive cash flow from operations.
DXCM had positive earnings in each of the past 5 years.
In the past 5 years DXCM always reported a positive cash flow from operatings.
1.2 Ratios
DXCM has a better Return On Assets (7.93%) than 90.37% of its industry peers.
DXCM has a Return On Equity of 23.61%. This is amongst the best in the industry. DXCM outperforms 95.19% of its industry peers.
Looking at the Return On Invested Capital, with a value of 14.54%, DXCM belongs to the top of the industry, outperforming 95.72% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for DXCM is above the industry average of 7.89%.
The 3 year average ROIC (11.25%) for DXCM is below the current ROIC(14.54%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.93% | ||
| ROE | 23.61% | ||
| ROIC | 14.54% |
ROA(3y)7.95%
ROA(5y)8.21%
ROE(3y)23.2%
ROE(5y)22.06%
ROIC(3y)11.25%
ROIC(5y)9.23%
1.3 Margins
Looking at the Profit Margin, with a value of 12.90%, DXCM belongs to the top of the industry, outperforming 90.91% of the companies in the same industry.
DXCM's Profit Margin has improved in the last couple of years.
The Operating Margin of DXCM (16.54%) is better than 87.17% of its industry peers.
In the last couple of years the Operating Margin of DXCM has grown nicely.
DXCM has a better Gross Margin (60.72%) than 60.96% of its industry peers.
In the last couple of years the Gross Margin of DXCM has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.54% | ||
| PM (TTM) | 12.9% | ||
| GM | 60.72% |
OM growth 3Y10.52%
OM growth 5Y8.87%
PM growth 3Y17.27%
PM growth 5Y15.84%
GM growth 3Y-3.98%
GM growth 5Y-0.72%
2. Health
2.1 Basic Checks
DXCM has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, DXCM has more shares outstanding
Compared to 5 years ago, DXCM has more shares outstanding
Compared to 1 year ago, DXCM has an improved debt to assets ratio.
2.2 Solvency
DXCM has an Altman-Z score of 6.24. This indicates that DXCM is financially healthy and has little risk of bankruptcy at the moment.
DXCM has a better Altman-Z score (6.24) than 82.89% of its industry peers.
DXCM has a debt to FCF ratio of 4.35. This is a neutral value as DXCM would need 4.35 years to pay back of all of its debts.
DXCM has a Debt to FCF ratio of 4.35. This is amongst the best in the industry. DXCM outperforms 83.96% of its industry peers.
DXCM has a Debt/Equity ratio of 0.57. This is a neutral value indicating DXCM is somewhat dependend on debt financing.
The Debt to Equity ratio of DXCM (0.57) is worse than 66.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.57 | ||
| Debt/FCF | 4.35 | ||
| Altman-Z | 6.24 |
ROIC/WACC1.72
WACC8.46%
2.3 Liquidity
A Current Ratio of 1.50 indicates that DXCM should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.50, DXCM is doing worse than 75.94% of the companies in the same industry.
A Quick Ratio of 1.32 indicates that DXCM should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.32, DXCM is doing worse than 66.84% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.5 | ||
| Quick Ratio | 1.32 |
3. Growth
3.1 Past
The earnings per share for DXCM have decreased by -0.60% in the last year.
DXCM shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 29.25% yearly.
DXCM shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.11%.
DXCM shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 22.27% yearly.
EPS 1Y (TTM)-0.6%
EPS 3Y35.38%
EPS 5Y29.25%
EPS Q2Q%0%
Revenue 1Y (TTM)9.11%
Revenue growth 3Y18.1%
Revenue growth 5Y22.27%
Sales Q2Q%12.49%
3.2 Future
DXCM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.56% yearly.
Based on estimates for the next years, DXCM will show a quite strong growth in Revenue. The Revenue will grow by 14.01% on average per year.
EPS Next Y25.5%
EPS Next 2Y25.23%
EPS Next 3Y24.56%
EPS Next 5Y22.56%
Revenue Next Year14.72%
Revenue Next 2Y15.07%
Revenue Next 3Y14.93%
Revenue Next 5Y14.01%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 54.28 indicates a quite expensive valuation of DXCM.
Based on the Price/Earnings ratio, DXCM is valued a bit cheaper than the industry average as 69.52% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 28.05. DXCM is valued rather expensively when compared to this.
Based on the Price/Forward Earnings ratio of 34.61, the valuation of DXCM can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of DXCM indicates a somewhat cheap valuation: DXCM is cheaper than 70.05% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of DXCM to the average of the S&P500 Index (37.67), we can say DXCM is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 54.28 | ||
| Fwd PE | 34.61 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, DXCM is valued a bit cheaper than 69.52% of the companies in the same industry.
72.73% of the companies in the same industry are more expensive than DXCM, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 61.06 | ||
| EV/EBITDA | 36.1 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
DXCM has an outstanding profitability rating, which may justify a higher PE ratio.
DXCM's earnings are expected to grow with 24.56% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.13
PEG (5Y)1.86
EPS Next 2Y25.23%
EPS Next 3Y24.56%
5. Dividend
5.1 Amount
No dividends for DXCM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:DXCM (7/28/2025, 10:07:09 AM)
89.565
+0.58 (+0.65%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners97.23%
Inst Owner Change0.15%
Ins Owners0.27%
Ins Owner Change12.88%
Market Cap35.12B
Analysts85.29
Price Target102.09 (13.98%)
Short Float %2.7%
Short Ratio2.85
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.87%
Min EPS beat(2)-11.66%
Max EPS beat(2)-4.09%
EPS beat(4)2
Avg EPS beat(4)-1.25%
Min EPS beat(4)-11.66%
Max EPS beat(4)9.24%
EPS beat(8)6
Avg EPS beat(8)14.5%
EPS beat(12)9
Avg EPS beat(12)12.8%
EPS beat(16)11
Avg EPS beat(16)12.29%
Revenue beat(2)0
Avg Revenue beat(2)-0.7%
Min Revenue beat(2)-1.2%
Max Revenue beat(2)-0.19%
Revenue beat(4)0
Avg Revenue beat(4)-2.01%
Min Revenue beat(4)-4.99%
Max Revenue beat(4)-0.19%
Revenue beat(8)2
Avg Revenue beat(8)-0.7%
Revenue beat(12)4
Avg Revenue beat(12)-0.65%
Revenue beat(16)6
Avg Revenue beat(16)-0.11%
PT rev (1m)0.27%
PT rev (3m)-1.11%
EPS NQ rev (1m)-0.71%
EPS NQ rev (3m)-7.25%
EPS NY rev (1m)0.06%
EPS NY rev (3m)0.53%
Revenue NQ rev (1m)-0.09%
Revenue NQ rev (3m)-0.43%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 54.28 | ||
| Fwd PE | 34.61 | ||
| P/S | 8.47 | ||
| P/FCF | 61.06 | ||
| P/OCF | 36.43 | ||
| P/B | 15.49 | ||
| P/tB | 16.35 | ||
| EV/EBITDA | 36.1 |
EPS(TTM)1.65
EY1.84%
EPS(NY)2.59
Fwd EY2.89%
FCF(TTM)1.47
FCFY1.64%
OCF(TTM)2.46
OCFY2.75%
SpS10.58
BVpS5.78
TBVpS5.48
PEG (NY)2.13
PEG (5Y)1.86
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.93% | ||
| ROE | 23.61% | ||
| ROCE | 18.47% | ||
| ROIC | 14.54% | ||
| ROICexc | 53.32% | ||
| ROICexgc | 60.37% | ||
| OM | 16.54% | ||
| PM (TTM) | 12.9% | ||
| GM | 60.72% | ||
| FCFM | 13.87% |
ROA(3y)7.95%
ROA(5y)8.21%
ROE(3y)23.2%
ROE(5y)22.06%
ROIC(3y)11.25%
ROIC(5y)9.23%
ROICexc(3y)35.45%
ROICexc(5y)29.66%
ROICexgc(3y)40.94%
ROICexgc(5y)33.19%
ROCE(3y)14.28%
ROCE(5y)11.73%
ROICexcg growth 3Y55.18%
ROICexcg growth 5Y18.96%
ROICexc growth 3Y50.14%
ROICexc growth 5Y16.58%
OM growth 3Y10.52%
OM growth 5Y8.87%
PM growth 3Y17.27%
PM growth 5Y15.84%
GM growth 3Y-3.98%
GM growth 5Y-0.72%
F-Score6
Asset Turnover0.61
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.57 | ||
| Debt/FCF | 4.35 | ||
| Debt/EBITDA | 1.42 | ||
| Cap/Depr | 172.69% | ||
| Cap/Sales | 9.38% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 105.79% | ||
| Profit Quality | 107.47% | ||
| Current Ratio | 1.5 | ||
| Quick Ratio | 1.32 | ||
| Altman-Z | 6.24 |
F-Score6
WACC8.46%
ROIC/WACC1.72
Cap/Depr(3y)175.34%
Cap/Depr(5y)240.83%
Cap/Sales(3y)9.32%
Cap/Sales(5y)10.84%
Profit Quality(3y)97.76%
Profit Quality(5y)73.64%
High Growth Momentum
Growth
EPS 1Y (TTM)-0.6%
EPS 3Y35.38%
EPS 5Y29.25%
EPS Q2Q%0%
EPS Next Y25.5%
EPS Next 2Y25.23%
EPS Next 3Y24.56%
EPS Next 5Y22.56%
Revenue 1Y (TTM)9.11%
Revenue growth 3Y18.1%
Revenue growth 5Y22.27%
Sales Q2Q%12.49%
Revenue Next Year14.72%
Revenue Next 2Y15.07%
Revenue Next 3Y14.93%
Revenue Next 5Y14.01%
EBIT growth 1Y2.68%
EBIT growth 3Y30.52%
EBIT growth 5Y33.11%
EBIT Next Year76.08%
EBIT Next 3Y38.17%
EBIT Next 5Y31.52%
FCF growth 1Y38.27%
FCF growth 3Y127.88%
FCF growth 5Y36.21%
OCF growth 1Y27.88%
OCF growth 3Y30.77%
OCF growth 5Y25.76%